Postmarketing Study of Empliciti in Korean Patients With Multiple Myeloma
NCT03660072 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2022-05-27
Summary
This study is a regulatory postmarketing surveillance study for Empliciti with a representative sample of the overall Korean multiple myeloma (MM) population.
Conditions
Interventions
- OTHER
-
Non-Interventional
Non-Interventional
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Eligibility
- Min Age
- 19 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-01-31
- Primary Completion
- 2022-10-28
- Completion
- 2022-10-28
Countries
- South Korea
Study Locations
More Related Trials
-
Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft
NCT03393273 ·Status: WITHDRAWN ·Phase: PHASE2
-
ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma
NCT06588660 ·Status: TERMINATED ·Phase: PHASE1
-
Daratumumab With DCEP for Multiple Myeloma With Plasmacytoma
NCT04065308 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
NCT04892446 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma
NCT01302392 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Natalizumab in Relapsed/Refractory Multiple Myeloma
NCT00675428 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
NCT02719613 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma
NCT02561962 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT06232707 ·Status: WITHDRAWN ·Phase: PHASE3
-
Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients
NCT04379817 ·Status: COMPLETED ·Phase: PHASE2
-
GO-203-2C + Bortezomib For Relapsed Or Refractory MM
NCT02658396 ·Status: WITHDRAWN ·Phase: PHASE1
-
Study of the Safety and Efficacy of an Investigational Drug in Adult Patients With Multiple Myeloma
NCT00036140 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of HG146 Capsule in Chinese Subjects with Relapsed and Refractory Multiple Myeloma
NCT03710915 ·Status: TERMINATED ·Phase: PHASE1
-
Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
NCT04150965 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies
NCT05191472 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
NCT01478048 ·Status: COMPLETED ·Phase: PHASE2
-
LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma
NCT03361306 ·Status: COMPLETED ·Phase: PHASE2
-
Study of ENMD-2076 in Patients With Multiple Myeloma
NCT00806065 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma
NCT03361748 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma
NCT04178902 ·Status: TERMINATED ·Phase: PHASE1
-
A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class Exposure
NCT05217082 ·Status: COMPLETED
-
Multiple Myeloma Patient Registry
NCT03180853 ·Status: TERMINATED
-
QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma
NCT01670994 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
NCT00461045 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04586426 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2